Literature DB >> 25911707

Value of sonographic bidirectional arterial flow combined with elastography for diagnosis of breast imaging reporting and data system category 4 breast masses.

Da Liu1, Ying Huang2, Dan Tian1, Jing Yin1, Li-Jun Deng1.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the role of bidirectional arterial flow combined with ultrasound elastography for differentiation of American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) category 4 masses.
METHODS: A total of 116 BI-RADS category 4 breast masses were evaluated with color Doppler sonography, spectral analysis, and elastography. The sensitivity, specificity, accuracy, positive and negative predictive values, and receiver operator characteristic curve were used to estimate the diagnostic performance for each modality and the combination method.
RESULTS: The combination method had the best sensitivity (81.1%) but less specificity (94.9%) and the best accuracy (90.5%). The discriminating power of the combined method (area under the curve [AUC], 0.880; 95% confidence interval [CI], 80.0%-96.0%) was significantly higher than that of bidirectional arterial flow (AUC, 0.818; 95% CI, 72.0%-91.6%; P< .01) and elastography (AUC, 0.765; 95% CI, 65.9%-87.0%; P< .01).
CONCLUSIONS: Bidirectional arterial flow evaluation, when combined with elastography, could potentially improve diagnostic accuracy for BI-RADS category 4 breast masses.
© 2015 by the American Institute of Ultrasound in Medicine.

Keywords:  Breast Imaging Reporting and Data System; arterial flow; bidirectional flow; breast cancer; breast ultrasound; elastography

Mesh:

Year:  2015        PMID: 25911707     DOI: 10.7863/ultra.35.5.759

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  1 in total

1.  Novel approach in the evaluation of ultrasound BI-RADS 3 & 4 breast masses with a combination method of elastography & Doppler.

Authors:  Anjuna Reghunath; Mahesh Kumar Mittal; Chintamani Chintamani; Rajni Prasad
Journal:  Indian J Med Res       Date:  2021-08       Impact factor: 5.274

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.